Treats relapsing forms of multiple sclerosis (MS). ANDA 209702, held by Somerset Theraps LLC. Teriflunomide.
As of Nov 16, 2026, ANDA 209702 (Teriflunomide), held by Somerset Theraps LLC, was first approved by FDA on Feb 28, 2020, with 3 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2020 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Discontinued |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Discontinued |
| Aug 22, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 29, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 22, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 28, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters